NEW YORK, March 11, 2019 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH) a development stage
biopharmaceutical company focused on unique targeted therapeutics
for patients suffering from indications such as atopic
dermatitis–also known as eczema–as well as dermatological and
chronic wound disorders, today announced Dr.
Jonathan Zippin has been named Senior Scientific
Advisor. Dr. Zippin will advise Hoth
Therapeutics on the design, development and implementation of
Hoth's proposed clinical study for atopic dermatitis in the
pediatric population.
Jonathan Zippin, M.D., Ph.D.,
FAAD, is Vice Chair of Research, Director Contact, Occupational,
and Photodermatitis Service, Associate Professor of Dermatology,
Associate Professor of Pharmacology, Associate Attending
Dermatologist, New York-Presbyterian Hospital, Department of
Dermatology, Weill Cornell Medicine.
Robb Knie, CEO of Hoth
Therapeutics, commented, "I am happy to have Jon's wealth of
experience and input to help advise on our proposed clinical trial
as we aim to bring a new therapeutic to market for those suffering
from atopic dermatitis. As a researcher and practicing
physician Jon has unique firsthand knowledge and experience in
trial planning, implementation and treatment."
Dr. Jonathan Zippin added "As a physician-scientist
who treats patients with allergic contact dermatitis and atopic
dermatitis, I am excited about the opportunity to help advise Hoth
Therapeutics on this important clinical trial."
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc., a Nevada corporation, is a
development stage biopharmaceutical company focused on unique
targeted therapeutics for patients suffering from indications such
as atopic dermatitis, also known as eczema. Hoth has exclusive
worldwide rights to the BioLexa Platform. Hoth intends to use the
BioLexa Platform to develop two different topical cream products:
(i) a product to treat eczema and (ii) a product that reduces
post-procedure infections, accelerates healing and improves
clinical outcomes for patients undergoing aesthetic dermatology
procedures. Hoth's initial focus will be on the development of the
BioLexa Platform for the treatment of eczema. Eczema is a
disease that results in inflammation of the skin and is
characterized by rash, red skin, and itchiness. Eczema is also
referred to as atopic dermatitis.
Forward Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the Securities and Exchange
Commission (the "SEC"), not limited to Risk Factors relating to its
patent business contained therein. Thus, actual results could be
materially different. The Company expressly disclaims any
obligation to update or alter statements whether as a result of new
information, future events or otherwise, except as required by
law.
Contact:
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-dr-jonathan-zippin-as-senior-scientific-advisor-300809727.html
SOURCE Hoth Therapeutics, Inc.